Efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysis

Backgroun/Aim. Although majority of guidelines recommend triazoles (voriconazole, posaconazole, itraconazole and isavuconazole) as first-line therapeutic option for treatment of invasive aspergillosis, echinocandins (caspofungin, micafungin and anidulafungin) are also used for this purpose. However,...

Full description

Bibliographic Details
Main Authors: Uzelac Sanja M., Živković-Zarić Radica S., Radovanović Milan R., Ranković Goran Ž., Jankovic Slobodan M.
Format: Article
Language:English
Published: Military Health Department, Ministry of Defance, Serbia 2020-01-01
Series:Vojnosanitetski Pregled
Subjects:
Online Access:http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800168U.pdf
_version_ 1818919459113402368
author Uzelac Sanja M.
Živković-Zarić Radica S.
Radovanović Milan R.
Ranković Goran Ž.
Jankovic Slobodan M.
author_facet Uzelac Sanja M.
Živković-Zarić Radica S.
Radovanović Milan R.
Ranković Goran Ž.
Jankovic Slobodan M.
author_sort Uzelac Sanja M.
collection DOAJ
description Backgroun/Aim. Although majority of guidelines recommend triazoles (voriconazole, posaconazole, itraconazole and isavuconazole) as first-line therapeutic option for treatment of invasive aspergillosis, echinocandins (caspofungin, micafungin and anidulafungin) are also used for this purpose. However, head-to-head comparison of triazoles and echinocandins for invasive aspergillosis was rarely target of clinical trials. The aim of this meta-analysis was to compare efficacy and safety of triazoles and echinocandins when used for treatment of patients with invasive aspergillosis. Methods. This meta-analysis was based on systematic search of literature and selection of high-quality evidence according to pre-set inclusion and exclusion criteria. The literature search was made for comparison of treatment with any of triazoles (isavuconazole, itraconazole, posaconazole or voriconazole) versus any of echinocandins (caspofungin, anidulafungin or micafungin). The effects of triazoles (itraconazole, posaconazole or voriconazole) and echinocandins (caspofungin, anidulafungin or micafungin) were summarized using RevMan 5.3.5 software, and heterogeneity assessed by the Cochrane Q test and I² values. Several types of bias were assessed, and publication bias was shown by the funnel plot and Egger’s regression. Results. Two clinical trials and three cohort studies were included in this meta-analysis. Mortality in patients with invasive aspergillosis who were treated with triazoles was significantly lower than in patients treated with echinocandins [odds ratio 0.29 (0.13, 0.67)], and rate of favorable response (overall treatment success) 12 weeks after the therapy onset was higher in patients treated with triazoles [3.05 (1.52, 6.13)]. On the other hand, incidence of adverse events was higher with triazoles than with echinocandins in patients treated for invasive aspergillosis [3.75 (0.89, 15.76)], although this difference was not statistically significant. Conclusion.Triazoles (voriconazole in the first place) could be considered as more effective and somewhat less safe therapeutic option than echinocandins for invasive aspergillosis: However, due to poor quality of studies included in this meta-analysis, definite conclusion should await results of additional, well designed clinical trials.
first_indexed 2024-12-20T01:06:11Z
format Article
id doaj.art-d4b6b2b285344f0d8cb2bbf06eecd37b
institution Directory Open Access Journal
issn 0042-8450
2406-0720
language English
last_indexed 2024-12-20T01:06:11Z
publishDate 2020-01-01
publisher Military Health Department, Ministry of Defance, Serbia
record_format Article
series Vojnosanitetski Pregled
spelling doaj.art-d4b6b2b285344f0d8cb2bbf06eecd37b2022-12-21T19:58:51ZengMilitary Health Department, Ministry of Defance, SerbiaVojnosanitetski Pregled0042-84502406-07202020-01-0177997498510.2298/VSP180528168U0042-84501800168UEfficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysisUzelac Sanja M.0Živković-Zarić Radica S.1Radovanović Milan R.2Ranković Goran Ž.3Jankovic Slobodan M.4University of Kragujevac, Faculty of Medical Sciences, Kragujevac, SerbiaUniversity of Kragujevac, Faculty of Medical Sciences, Kragujevac, SerbiaUniversity of Kragujevac, Faculty of Medical Sciences, Kragujevac, SerbiaUniversity of Niš, Faculty of Medicine, Niš, SerbiaUniversity of Kragujevac, Faculty of Medical Sciences, Kragujevac, SerbiaBackgroun/Aim. Although majority of guidelines recommend triazoles (voriconazole, posaconazole, itraconazole and isavuconazole) as first-line therapeutic option for treatment of invasive aspergillosis, echinocandins (caspofungin, micafungin and anidulafungin) are also used for this purpose. However, head-to-head comparison of triazoles and echinocandins for invasive aspergillosis was rarely target of clinical trials. The aim of this meta-analysis was to compare efficacy and safety of triazoles and echinocandins when used for treatment of patients with invasive aspergillosis. Methods. This meta-analysis was based on systematic search of literature and selection of high-quality evidence according to pre-set inclusion and exclusion criteria. The literature search was made for comparison of treatment with any of triazoles (isavuconazole, itraconazole, posaconazole or voriconazole) versus any of echinocandins (caspofungin, anidulafungin or micafungin). The effects of triazoles (itraconazole, posaconazole or voriconazole) and echinocandins (caspofungin, anidulafungin or micafungin) were summarized using RevMan 5.3.5 software, and heterogeneity assessed by the Cochrane Q test and I² values. Several types of bias were assessed, and publication bias was shown by the funnel plot and Egger’s regression. Results. Two clinical trials and three cohort studies were included in this meta-analysis. Mortality in patients with invasive aspergillosis who were treated with triazoles was significantly lower than in patients treated with echinocandins [odds ratio 0.29 (0.13, 0.67)], and rate of favorable response (overall treatment success) 12 weeks after the therapy onset was higher in patients treated with triazoles [3.05 (1.52, 6.13)]. On the other hand, incidence of adverse events was higher with triazoles than with echinocandins in patients treated for invasive aspergillosis [3.75 (0.89, 15.76)], although this difference was not statistically significant. Conclusion.Triazoles (voriconazole in the first place) could be considered as more effective and somewhat less safe therapeutic option than echinocandins for invasive aspergillosis: However, due to poor quality of studies included in this meta-analysis, definite conclusion should await results of additional, well designed clinical trials.http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800168U.pdfaspergillosistriazolesechinocandinsmeta-analysis
spellingShingle Uzelac Sanja M.
Živković-Zarić Radica S.
Radovanović Milan R.
Ranković Goran Ž.
Jankovic Slobodan M.
Efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysis
Vojnosanitetski Pregled
aspergillosis
triazoles
echinocandins
meta-analysis
title Efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysis
title_full Efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysis
title_fullStr Efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysis
title_full_unstemmed Efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysis
title_short Efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysis
title_sort efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis a meta analysis
topic aspergillosis
triazoles
echinocandins
meta-analysis
url http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800168U.pdf
work_keys_str_mv AT uzelacsanjam efficacyandsafetyoftriazolesversusechinocandinsinthetreatmentofinvasiveaspergillosisametaanalysis
AT zivkoviczaricradicas efficacyandsafetyoftriazolesversusechinocandinsinthetreatmentofinvasiveaspergillosisametaanalysis
AT radovanovicmilanr efficacyandsafetyoftriazolesversusechinocandinsinthetreatmentofinvasiveaspergillosisametaanalysis
AT rankovicgoranz efficacyandsafetyoftriazolesversusechinocandinsinthetreatmentofinvasiveaspergillosisametaanalysis
AT jankovicslobodanm efficacyandsafetyoftriazolesversusechinocandinsinthetreatmentofinvasiveaspergillosisametaanalysis